Robert L Ferris1, Zubair Baloch2, Victor Bernet3, Amy Chen4, Thomas J Fahey5, Ian Ganly6, Steven P Hodak7, Electron Kebebew8, Kepal N Patel9, Ashok Shaha6, David L Steward10, Ralph P Tufano11, Sam M Wiseman12, Sally E Carty13. 1. 1 Division of Head and Neck Surgery, Department of Otolaryngology, University of Pittsburgh Cancer Institute , Pittsburgh, Pennsylvania. 2. 2 Department of Pathology, University of Pennsylvania Medical Center , Philadelphia, Pennsylvania. 3. 3 Department of Endocrinology, Mayo Clinic , Jacksonville, Florida. 4. 4 Department of Otolaryngology/Head and Neck Surgery, Emory University , Atlanta, Georgia . 5. 5 Department of Surgery, New York Presbyterian Hospital , New York, New York. 6. 6 Head and Neck Service, Memorial Sloan-Kettering Cancer Center , New York, New York. 7. 7 Division of Endocrinology, New York University Medical Center , New York, New York. 8. 8 Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute , Bethesda, Maryland. 9. 9 Division of Endocrine Surgery, New York University Medical Center , New York, New York. 10. 10 Department of Otolaryngology/Head and Neck Surgery, University of Cincinnati Medical Center , Cincinnati, Ohio. 11. 11 Department of Otolaryngology/Head and Neck Surgery, Johns Hopkins University , Baltimore, Maryland. 12. 12 Department of Surgery, Division of General Surgery, St. Paul's Hospital and University of British Columbia , Vancouver, Canada . 13. 13 Division of Endocrine Surgery, Department of Surgery, University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: Recent advances in research on thyroid carcinogenesis have yielded applications of diagnostic molecular biomarkers and profiling panels in the management of thyroid nodules. The specific utility of these novel, clinically available molecular tests is becoming widely appreciated, especially in perioperative decision making by the surgeon regarding the need for surgery and the extent of initial resection. METHODS: A task force was convened by the Surgical Affairs Committee of the American Thyroid Association and was charged with writing this article. RESULTS/ CONCLUSIONS: This review covers the clinical scenarios by cytologic category for which the thyroid surgeon may find molecular profiling results useful, particularly for cases with indeterminate fine-needle aspiration cytology. Distinct strengths of each ancillary test are highlighted to convey the current status of this evolving field, which has already demonstrated the potential to streamline decision making and reduce unnecessary surgery, with the accompanying benefits. However, the performance of any diagnostic test, that is, its positive predictive value and negative predictive value, are exquisitely influenced by the prevalence of cancer in that cytologic category, which is known to vary widely at different medical centers. Thus, it is crucial for the clinician to know the prevalence of malignancy within each indeterminate cytologic category, at one's own institution. Without this information, the performance of the diagnostic tests discussed below may vary substantially.
BACKGROUND: Recent advances in research on thyroid carcinogenesis have yielded applications of diagnostic molecular biomarkers and profiling panels in the management of thyroid nodules. The specific utility of these novel, clinically available molecular tests is becoming widely appreciated, especially in perioperative decision making by the surgeon regarding the need for surgery and the extent of initial resection. METHODS: A task force was convened by the Surgical Affairs Committee of the American Thyroid Association and was charged with writing this article. RESULTS/ CONCLUSIONS: This review covers the clinical scenarios by cytologic category for which the thyroid surgeon may find molecular profiling results useful, particularly for cases with indeterminate fine-needle aspiration cytology. Distinct strengths of each ancillary test are highlighted to convey the current status of this evolving field, which has already demonstrated the potential to streamline decision making and reduce unnecessary surgery, with the accompanying benefits. However, the performance of any diagnostic test, that is, its positive predictive value and negative predictive value, are exquisitely influenced by the prevalence of cancer in that cytologic category, which is known to vary widely at different medical centers. Thus, it is crucial for the clinician to know the prevalence of malignancy within each indeterminate cytologic category, at one's own institution. Without this information, the performance of the diagnostic tests discussed below may vary substantially.
Authors: P Sean Walsh; Jonathan I Wilde; Edward Y Tom; Jessica D Reynolds; Daphne C Chen; Darya I Chudova; Moraima Pagan; Daniel G Pankratz; Mei Wong; James Veitch; Lyssa Friedman; Robert Monroe; David L Steward; Mark A Lupo; Richard B Lanman; Giulia C Kennedy Journal: J Clin Endocrinol Metab Date: 2012-10-18 Impact factor: 5.958
Authors: Lindsey M Kelly; Guillermo Barila; Pengyuan Liu; Viktoria N Evdokimova; Sumita Trivedi; Federica Panebianco; Manoj Gandhi; Sally E Carty; Steven P Hodak; Jianhua Luo; Sanja Dacic; Yan P Yu; Marina N Nikiforova; Robert L Ferris; Daniel L Altschuler; Yuri E Nikiforov Journal: Proc Natl Acad Sci U S A Date: 2014-02-03 Impact factor: 11.205
Authors: Jeffrey J Houlton; Gordon H Sun; Nella Fernandez; Qihui Jim Zhai; Fred Lucas; David L Steward Journal: Arch Otolaryngol Head Neck Surg Date: 2011-11
Authors: N Paul Ohori; Marina N Nikiforova; Karen E Schoedel; Shane O LeBeau; Steven P Hodak; Raja R Seethala; Sally E Carty; Jennifer B Ogilvie; Linwah Yip; Yuri E Nikiforov Journal: Cancer Cytopathol Date: 2010-02-25 Impact factor: 5.284
Authors: Yuri E Nikiforov; Sally E Carty; Simon I Chiosea; Christopher Coyne; Umamaheswar Duvvuri; Robert L Ferris; William E Gooding; Steven P Hodak; Shane O LeBeau; N Paul Ohori; Raja R Seethala; Mitchell E Tublin; Linwah Yip; Marina N Nikiforova Journal: Cancer Date: 2014-09-10 Impact factor: 6.860
Authors: Pablo Valderrabano; Laila Khazai; Zachary J Thompson; Marino E Leon; Kristen J Otto; Julie E Hallanger-Johnson; J Trad Wadsworth; Bruce M Wenig; Christine H Chung; Barbara A Centeno; Bryan McIver Journal: Thyroid Date: 2017-09-14 Impact factor: 6.568
Authors: David F Schneider; Linda M Cherney Stafford; Nicole Brys; Caprice C Greenberg; Courtney J Balentine; Dawn M Elfenbein; Susan C Pitt Journal: Endocr Pract Date: 2017-01-17 Impact factor: 3.443
Authors: Marcos A S de Oliveira; Michael Campbell; Alaa M Afify; Eric C Huang; James W Chan Journal: Biomed Opt Express Date: 2019-08-05 Impact factor: 3.732
Authors: I J Nixon; C Suárez; R Simo; A Sanabria; P Angelos; A Rinaldo; J P Rodrigo; L P Kowalski; D M Hartl; M L Hinni; J P Shah; A Ferlito Journal: Eur J Surg Oncol Date: 2016-08-11 Impact factor: 4.424